Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3 - PubMed (original) (raw)
. 1986 Sep 15;137(6):1816-21.
- PMID: 3091691
Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3
J L Ceuppens et al. J Immunol. 1986.
Abstract
Activation of human peripheral blood T cells by the anti-CD3 antibody OKT3 has been shown to require not only cross-linking of CD3 molecules with multimeric binding of the Fc part of OKT3 to a solid support, but also a second accessory cell-provided signal. Accordingly, measurement of T cell activation in cultures of highly enriched T cells with solid-phase-bound OKT3 can be used to investigate whether other agents can replace accessory cells. In this study we examined the capacity of anti-CD5 monoclonal antibodies to provide the additional activation signal. Resting T cells were prepared by isolating E rosette-positive cells, by removing OKM1(+) and HLA-DR(+) cells by panning, and by subsequent treatment of the cells with L-leucine methyl ester to kill remaining monocytes. These T cells were unresponsive to phytohemagglutinin (PHA) or to solid-phase-bound OKT3. However, when cultured in the presence of an anti-CD5 monoclonal antibody (anti-Leu-1, OKT1, or anti-T1), a proliferative response to solid-phase-bound OKT3 (but not to soluble OKT3 or to PHA) was observed. Anti-CD5 had no functional effect by itself, but in association with solid-phase-bound OKT3 it enhanced IL 2 receptor expression and IL 2 production and it initiated T cell proliferation. T cell proliferation under these conditions could be inhibited by an IL 2 receptor blocking antibody anti-Tac, thus confirming that anti-CD5 provides the second signal for an IL 2-dependent pathway of T cell proliferation. Preincubation of T cells with anti-Leu-1 or OKT1 resulted in complete loss of CD5 antigenicity, and such CD5 modulation was sufficient to induce a proliferative response to solid-phase-bound OKT3. It is concluded that in T cell activation by solid-phase-bound OKT3 the necessary additional signal can be provided by modulation of the CD5 antigen with an anti-CD5 antibody. CD5 therefore appears to be a positive signal receptor on the T cell membrane, whose physiologic ligand still has to be determined.
Similar articles
- Mechanisms by which accessory cells contribute in growth of resting T lymphocytes initiated by OKT3 antibody.
Palacios R. Palacios R. Eur J Immunol. 1985 Jul;15(7):645-51. doi: 10.1002/eji.1830150702. Eur J Immunol. 1985. PMID: 3924633 - Requirements for T cell activation by OKT3 monoclonal antibody: role of modulation of T3 molecules and interleukin 1.
Schwab R, Crow MK, Russo C, Weksler ME. Schwab R, et al. J Immunol. 1985 Sep;135(3):1714-8. J Immunol. 1985. PMID: 3926880 - Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation.
Verwilghen J, Baroja ML, Van Vaeck F, Van Damme J, Ceuppens JL. Verwilghen J, et al. Immunology. 1991 Feb;72(2):269-76. Immunology. 1991. PMID: 1826671 Free PMC article. - The activation of T lymphocytes.
Bockenstedt LK, Goldsmith MA, Koretzky GA, Weiss A. Bockenstedt LK, et al. Rheum Dis Clin North Am. 1987 Dec;13(3):411-30. Rheum Dis Clin North Am. 1987. PMID: 2963355 Review. - An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
Norman DJ. Norman DJ. Transplant Proc. 1988 Dec;20(6):1248-52. Transplant Proc. 1988. PMID: 2974204 Review.
Cited by
- Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.
Elghawy O, Cao M, Xu J, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Tavakkoli M, Ruella M, Barta SK. Elghawy O, et al. Cancers (Basel). 2024 Oct 9;16(19):3430. doi: 10.3390/cancers16193430. Cancers (Basel). 2024. PMID: 39410047 Free PMC article. - The influence of HLA genetic variation on plasma protein expression.
Krishna C, Chiou J, Sakaue S, Kang JB, Christensen SM, Lee I, Aksit MA, Kim HI, von Schack D, Raychaudhuri S, Ziemek D, Hu X. Krishna C, et al. Nat Commun. 2024 Jul 31;15(1):6469. doi: 10.1038/s41467-024-50583-8. Nat Commun. 2024. PMID: 39085222 Free PMC article. - CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.
He M, Roussak K, Ma F, Borcherding N, Garin V, White M, Schutt C, Jensen TI, Zhao Y, Iberg CA, Shah K, Bhatia H, Korenfeld D, Dinkel S, Gray J, Ulezko Antonova A, Ferris S, Donermeyer D, Lindestam Arlehamn C, Gubin MM, Luo J, Gorvel L, Pellegrini M, Sette A, Tung T, Bak R, Modlin RL, Fields RC, Schreiber RD, Allen PM, Klechevsky E. He M, et al. Science. 2023 Feb 17;379(6633):eabg2752. doi: 10.1126/science.abg2752. Epub 2023 Feb 17. Science. 2023. PMID: 36795805 Free PMC article. - Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies.
Sui S, Li Z, Tan J, Wang L, Luo G, Zeng C, Luo OJ, Chen C, Li Y. Sui S, et al. J Oncol. 2022 Aug 9;2022:2787426. doi: 10.1155/2022/2787426. eCollection 2022. J Oncol. 2022. PMID: 35983088 Free PMC article. - CD5 Controls Gut Immunity by Shaping the Cytokine Profile of Intestinal T Cells.
Schuster C, Kiaf B, Hatzihristidis T, Ruckdeschel A, Nieves-Bonilla J, Ishikawa Y, Zhao B, Zheng P, Love PE, Kissler S. Schuster C, et al. Front Immunol. 2022 Jun 2;13:906499. doi: 10.3389/fimmu.2022.906499. eCollection 2022. Front Immunol. 2022. PMID: 35720357 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials